Jpmorgan Chase & CO Athenex, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.12 - $0.21 $739 - $1,294	-6,163 Reduced 64.17%	3,441 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $1.11 $754 - $3,488	3,143 Added 48.65%	9,604 $3,000
Q2 2022 Aug 11, 2022	SELL	$0.41 - $0.91 $55,381 - $122,919	-135,076 Reduced 95.44%	6,461 $3,000
Q1 2022 May 11, 2022	BUY	$0.79 - $1.59 $6,053 - $12,184	7,663 Added 5.72%	141,537 $118,000
Q4 2021 Feb 10, 2022	SELL	$1.36 - $2.94 $2,099 - $4,539	-1,544 Reduced 1.14%	133,874 $182,000
Q3 2021 Nov 12, 2021	BUY	$2.97 - $4.84 $402,191 - $655,423	135,418 New	135,418 $408,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.